Biogen maps way to future factory


Biogen Idec sees the bioprocessing factory of its future. It's not some pie-in-the-sky concept, but the result of a technology map created collaboratively by the company's heads of engineering, development and manufacturing to help coordinate their forward-looking thinking.

Here's what the company sees: smaller, more flexible facilities based on new technologies to improve production results in line with changes in demand and changes in the pace of production. The vision includes little of the $500 million to $1 billion worth of stainless steel bioreactors, piping, instrumentation, equipment and support systems of traditional bioprocess plants, reports Investor's Business Daily. Shiny two- to three-story bioreactors will give way to much smaller disposable bags and single-use technology components.

"By changing the equipment, the time it takes to bring into operation a new plant is transformed," says John Cox, EVP for pharma ops and technology, in the article.


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The map-building is ultimately a silo-buster, too. The technique helps the company leaders coordinate their thinking. And as their coordinated ideas become manufacturing and operations reality, traditional barriers between the three functions will no longer be sustained.


Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.